Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: tsigprofit who wrote (6039)	10/15/2001 9:41:06 PM
From: John F. Poteraske	Respond to of 48461

Here was a little bit of info that I read inside of a article. An anthrax vaccine alternative? A Massachusetts company could soon have an alternative to the anthrax vaccine, following a recent deal. Avant, of Needham, Massachusetts, has landed a licensing deal that will give DynPort Vaccine Company access to Avant's advanced vaccine patents. A company spokeswoman said the Defense Department had asked Avant not to discuss the deal's relation to anthrax. But a member of Avant's scientific advisory board said it could be useful against the disease. "They're going great guns with travelers' vaccines such as cholera and typhoid," said Dr. Mark Davis. "Anthrax would just be another bug." The company says it has conducted preclinical work in vaccines for anthrax and other diseases. Details of the agreement were not disclosed. news.lycos.com Scroll Down Any investment potential here??